Guaifenesin Oral Solution Recalled Due to Incomplete Stability Studies
Akorn, Inc. is recalling all lots of Guaifenesin Oral Solution nationwide due to CGMP deviations. The manufacturer ceased operations before completing required stability testing to verify the product's safety and efficacy.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: FDA Class II recall issued due to CGMP deviations stemming from the manufacturer's closure and inability to complete required stability studies. No illnesses or injuries have been reported; the recall is based on the theoretical risk posed by unverified product stability.
Plain-English summary
Akorn, Inc. is recalling all lots of Guaifenesin Oral Solution, 300 mg/15 mL (sugar-free, alcohol-free, Rx only, for institutional use), distributed nationwide in the USA and Puerto Rico.
The recall was initiated due to Current Good Manufacturing Practice (CGMP) deviations. The manufacturer went out of business and could no longer continue the stability studies required to verify that the product maintains its safety and efficacy throughout its shelf life.
Healthcare facilities and institutional users who have received this product should consult with their pharmacist or healthcare provider regarding appropriate actions. Patients taking this medication should speak with their healthcare provider about alternative treatments.
The recalled product
- Product
- Guaifenesin Oral Solution, 300 mg/ 15 mL, Sugar Free/Alcohol Free, Rx Only, For Institutional Use Only, Hi-Tech Pharmacal Co., Inc., Amityville, NY 11701. ALL NDCs
- Manufacturer
- Akorn, Inc.
- Category
- Drug
- Hazard
- cgmp-deviation
- stability-unverified
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (1)
- All Lots
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27